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placebo and were followed up for a median of 4.1 years. Anacetrapib met the primary end point. A first major coronary event (a composite of coronary death, myocardial infarction, or coronary revascularization) occurred in 10.8% of patients in the anacetrapib group vs. 11.8% of patients in the placebo group (a 9% reduction in risk; P = 0.004). Anacetrapib enhanced HDL-cholesterol by more than two-fold (104%) and decreased LDL-cholesterol by at least 20%. No substantial safety issues were identified during the follow-up although patients under anacetrapib showed a slightly higher blood pressure (0.7 mm Hg systolic/0.3 mm Hg diastolic) and a higher risk of developing an estimated glomerular filtration rate of <60 ml/min/1.73 m 2 (11.5 vs. 10.6%; P = 0.04). A decrease in new-onset diabetes was also observed in the anacetrapib group (5.3 vs. 6%; P = 0.049). Her research activities focus on cardio-metabolic diseases, thrombosis, atherosclerosis and ischaemic heart disease. She has published over 495 articles in highly qualified scientific journals with her work highly quoted in the scientific literature (Citations: 27.509; h-index 69). She has written more of 250 reviews and book chapters The REVEAL trial results were better than those reached in previous trials testing CETP inhibitors. Indeed ILLUMINATE was prematurely terminated in 2007 because of excessive risk of death among patients allocated to receive torvetrapib. 2 Dal-OUTCOMES testing dalcetrapib 3 and ACCELERATE testing evacetrapib 4 were stopped after around 2-year follow-up due to futility, in 2012 and 2015, respectively. Instead, the REVEAL trial has shown reduction, albeit modest, in the incidence of cardiovascular events in high-risk patients, accordingly to the achieved reduction in LDLc level. However, these results and the clinical profile for anacetrapib have been considered disappointing and 'unable to support regulatory filings' and the Anacetrapib development programme has been stopped (Merck Newsroom Home statement 11 October 2017). This seems the end to this class of drugs designed to investigated the reduction of cardiovascular residual risk after statin treatment. CETP plays a prominent role in the transfer of cholesterol esters from the cardioprotective HDL particles to the potentially atherogenic ApoBcontaining particles. Hence, drugs that powerfully inhibit CETP do not result in decrease in total cholesterol but rather a shift in cholesterol content from LDL into HDL (i.e. increase HDL-cholesterol and decrease LDL-cholesterol). Solid evidence from statin therapy trials estimated a 10% relative reduction in the primary outcome upon declining LDLcholesterol to levels comparable to that achieved in the REVEAL trial. 5 Accordingly, the cardiovascular benefit reached by anacetrapib was likely directly related to the lowering of atherogenic LDL-cholesterol rather than HDL-cholesterol rising. The large increase in HDL-cholesterol achieved by all CETP inhibitors has indeed proven to have no impact in cardiovascular risk reduction.
Although a consistent body of epidemiological and clinical data evidenced that high HDL-cholesterol levels provided substantial protection against the development of cardiovascular events, this is true for primary prevention and mainly in conditions of average/low LDL levels. Within the last years it has become evident that under pathological conditions, dislipemia and atherosclerotic cardiovascular disease, HDL particles suffer changes in their structure and composition, which are related with loss of beneficial properties or even gain of dysfunction. [6] [7] [8] The raise of HDLcholesterol induced by CETP inhibition mostly reflected an increase in the level of enlarged, mature and cholesterol-rich HDL particles with impaired protective function. The study at HDL subtypes and HDL cargo in patients treated with a CETP inhibitor, if ever conducted; cold provide information on the characteristics of structure/function relations in HDL remodelling. Future studies need to focus on HDL and not HDLc to be able to understand the effects of this particle in atherosclerosis. In addition to ApoA-1, HDL micelles contain many other proteins involved not only in lipid metabolism, but also in complement regulation, acute phase response and proteinase inhibition. 9 The role of HDL, and not HDL-c levels, in vascular biology and atherosclerotic plaque development as well as the HDL role in cardiovascular risk assessment, risk stratification and prognosis, needs careful investigation. Similarly, the investigation of the direct impact of risk factors and co-morbidities in HDL remodelling and in HDLmediated protection is still waiting. The highly remodelled HDL particle modifies quality and function depending on the environment. Identification of the protein changes that occur in CAD patients and their association to CVD progression may provide new light for future therapies.
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